  The identification of genomic, molecular and clinical markers predictive of
patient survival is important for developing personalized disease prevention,
diagnostic and treatment approaches. Modern omics technologies have made it
possible to investigate the prognostic impact of markers at multiple molecular
levels, including genomics, epigenomics (e.g. DNA methylation),
transcriptomics, proteomics and metabolomics, and how these potential risk
factors complement clinical characterization of patients for survival
prognosis. However, the massive sizes of the omics data sets pose challenges
for studying relationships between the molecular information and patients'
survival outcomes. We present a general workflow for survival analysis, with
emphasis on dealing with high-dimensional omics data as inputs when identifying
survival-associated omics features and validating survival models. In
particular, we focus on commonly used Cox-type penalized regressions and
hierarchical Bayesian models for feature selection in survival analysis, but
the framework and pipeline are applicable more generally. In cases where
multi-omics data are available for survival modelling, an extra caution is
needed to account for the underlying structure both within and between the
omics data sets and features. A step-by-step R tutorial using The Cancer Genome
Atlas survival and omics data for the execution and evaluation of survival
models has been made available at
\url{https://ocbe-uio.github.io/survomics/survomics.html}.
